Objectives: The aim of the study was to test in vitro activities of the novel des-F(6)-quinolone DX-619 against methicillin-resistant staphylococci (MRS) isolated in hospitals and communities and to compare its activity with other quinolones, sitafloxacin and levofloxacin, and antibiotics used for the treatment of methicillin-resistant Staphylococcus aureus infection, including vancomycin, teicoplanin, arbekacin, linezolid and quinupristin/dalfopristin.
Introduction
Methicillin-resistant staphylococci (MRS) represented by methicillinresistant Staphylococcus aureus (MRSA) have become major nosocomial pathogens worldwide. Strains are commonly resistant to most of the clinically available antimicrobial agents and highly resistant to b-lactams. 1 Glycopeptides, vancomycin and teicoplanin, have been used for the treatment of infections caused by these multiresistant MRS. However, susceptibility of MRS to glycopeptides has been changing. Vancomycin-intermediate S. aureus (VISA) strains 2 or glycopeptide-intermediate S. aureus strains and vancomycin-resistant MRSA strains 3 have been reported. An oxazolidinone antibiotic, linezolid, has been introduced as a new therapeutic agent. However, linezolidresistant S. aureus first emerged in 2001. 4 The development of other novel antistaphylococcal agents has been actively pursued. DX-619 was developed as a drug used for the treatment of infections caused by multidrug-resistant Gram-positive organisms.
In this study, we tested the in vitro activity of DX-619 in comparison with seven reference compounds. As the epidemiology of MRS has been changing and MRS have frequently become isolated from community-associated infections, 5 we tested susceptibilities of isolates from both hospitals and the community to DX-619. 
Materials and methods

DX
and Staphylococcus xylosus (n ¼ 1)]. All tested strains carried mecA, which was confirmed by PCR as described previously. 6 MICs were determined by the agar dilution method as recommended by the CLSI (formerly NCCLS) using S. aureus FDA 209-P and S. aureus ATCC 29213 as reference strains.
The nucleotide sequences of the quinolone resistancedetermining regions (QRDRs) of gyrA, gyrB, grlA and grlB genes in the six MRSA strains (four from Korea, JCSC108, JCSC116, JCSC129 and JCSC133, and two from Japan, JCSC378 and JCSC1111) with the highest MIC value (2 mg/L) of DX-619 were determined by amplifying DNA fragments by PCR as described previously 7 with primer pairs as follows: gyrA, gyrA-up, TGGCTG-AATTACCTCAATCAAG and gyrA-down, CTTCAATAACTGCAC-GAGAACG; gyrB, gyrB-up, ATACACGTGAAGGTATGACAGC and gyrB-down, TCCAAGACCTTTGTATCGTGCA; grlA, grlA-up, TTAGGTGATCGCTTTGGAAGAT and grlA-down, TACCTGTAG-AACCATTCACTAG and grlB, grlB-up, ACTTCTGAAGCTAG-AAGTGCTG and grlB-down, TTTCTGGGTTCATCGTCGTTTC. Nucleotide sequencing was carried out using a BigDye Terminator version 3.1 Cycle Sequencing Kit (Applied Biosystems, CA, USA) and 3730 DNA Analyzer (Applied Biosystems and Hitachi, Ltd, Tokyo Japan), according to manufacturers' instructions.
Results and discussion
We tested the in vitro activities of DX-619 and seven reference compounds against different categories of MRS (Table 1 ). In the case of vancomycin-susceptible HA-MRSA strains, the proportions of susceptible strains to four antibiotics, vancomycin, teicoplanin, linezolid and quinupristin/dalfopristin, were judged to be 98.8% based on the criteria of the CLSI, but only 21.3% of strains were susceptible to levofloxacin (Table 1B) . Linezolid and quinupristin/dalfopristin were effective against VISA strains that showed reduced susceptibility to vancomycin (MIC ¼ 2-8 mg/L) and teicoplanin (MIC ¼ 4-32 mg/L) ( Table 1C ). All these strains were resistant to levofloxacin. DX-619 showed the lowest MIC 50 and MIC 90 values (0.06 and 0.25 mg/L) for 103 HA-MRSA strains, irrespective of the susceptibility to glycopeptides (Table 1A) .
CA-MRSA/NORSA strains were susceptible to all eight tested compounds (Table 1D) .
Susceptibilities of MRCoNS strains are similar to those of MRSA (Table 1E - Almost all CA-MRCoNS strains were susceptible to all eight tested compounds. However, 5.4% of them were resistant to teicoplanin and 12% to levofloxacin. Among the tested compounds, DX-619 again showed the highest activity against all tested MRCoNS.
It is well known that quinolone resistance can occur as a result of mutation in DNA gyrase and topoisomerase IV, which are the targets for this class of antimicrobial. Among the tested strains, six HA-MRSA strains showed MIC values of 2 mg/L of DX-619, which is the highest reported from previous clinical staphylococcal isolates. 8, 9 These strains were highly resistant to the other quinolones tested with MIC values of 32 mg/L for sitafloxacin and .128 mg/L for levofloxacin. To determine the molecular basis for quinolone resistance in these strains, we determined the nucleotide sequences of the QRDRs of gyrAB and grlAB of these six strains. Interestingly, all six strains isolated from two countries, Korea and Japan, shared identical mutations within gyrA and grlA. There were four point mutations in QRDRs of gyrA and grlA genes, whereas no mutation was found in QRDRs of gyrB and grlB genes. The four mutations were located in a4 domains of GyrA and GrlA: in GyrA, at codon 84 Ser (TCA) to Leu (TTA) and at codon 85 Ser (TCT) to Pro (CCT); and in GrlA, at codon 80 Ser (TCC) to Phe (TTC) and at codon 84 Glu (GAA) to Lys (GAA).
Des-F(6)-quinolone DX-619 showed extremely low MIC values for two reference S. aureus strains, FDA 209-P and ATCC 29213, with MICs of 0.008 and 0.016 mg/L, respectively. Although MIC values for clinical isolates increased at most 32-fold, it was still potent against all categories of MRS including strains resistant to clinically available quinolones with MICs ranging from 0.008 to 2 mg/L. This good activity could be a function of a high affinity for target enzymes and/or a structure favourable for accumulation within the cell.
DX-619 may become a useful alternative for the treatment of MRS infection. Preliminary studies by Daiichi Sankyo Co. Ltd have suggested that DX-619 has a promising safety profile. Further studies on toxicity, pharmacokinetics and pharmacodynamics of DX-619 are awaited. 
